Stock Groups

Merck, Pfizer Gain on Deals With Britain for Antivirals -Breaking

© Reuters.

By Dhirendra Tripathi – Stocks of Merck (NYSE:) and Pfizer (NYSE:) rose over 2% each Wednesday as Britain contracted supplies of their yet-to-be-approved Covid-19 antivirals.

“We may soon have a new defense in our arsenal with two new antiviral drugs that we have secured,” Health Minister Sajid Javid said in a statement.

Britain said it had secured 480,000 courses of Merck’s molnupiravir, an antiviral pill which can be used in non-hospitalized patients. The company is yet to apply with drug regulators for approval to the medicine.

The country has also secured 250,000 courses of Pfizer’s PF- 07321332 / ritonavir antiviral.

Merck claims that the pill can halve the risks of hospitalization and death from Covid. The company is developing the drug with Ridgeback Biotherapeutics. If approved, it could become the first oral antiviral to combat the pandemic.

Both the antivirals would need approval by the Medicines and Healthcare products Regulatory Agency before being used, the government said.

Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures) and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn`t bear any responsibility for any trading losses you might incur as a result of using this data.

Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.

Mike Robinson
Mike covers the financial, utilities and biotechnology sectors for Street Register. He has been writing about investment and personal finance topics for almost 12 years. Mike has an MBA in Finance from Wake Forest University.